Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer
Status:
Active, not recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and
tolerability of the combination and to identify a RP2D.
Part B:
Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or
MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their
recurrent/persistent or metastatic cervical cancer.